INDOCO REMEDIES LTD.

Indoco Remedies Ltd has announced that its Board of Directors will convene on October 27, 2026. The primary agenda item is the consideration and approval of the un-audited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. Concurrently, the trading window for designated persons and their immediate relatives will remain closed until October 29, 2026, which is 48 hours after the financial results are declared.

Indoco Remedies Ltd has issued a notice to shareholders holding shares in physical mode, mandating the submission of PAN, KYC, and Bank details to the Registrar and Transfer Agent (RTA), MUFG Intime India Private Limited. This is in compliance with SEBI's Master Circular dated February 6, 2026. Physical shareholders who fail to update these details will be ineligible for service requests and payments like dividends after April 1, 2024. The company also emphasizes the mandatory electronic mode for dividend payments and encourages conversion of physical shares to demat form.

Indoco Remedies Limited announced the incorporation of its wholly-owned subsidiary, "Warren Lifesciences Private Limited" (WLPL), on September 26, 2026. This follows an approval by the Committee of Executive Directors on September 18, 2026. WLPL is incorporated under the provisions of the Companies Act, 2013, with an authorised share capital of ₹1,00,000, divided into 10,000 equity shares of ₹10 each. Indoco Remedies will hold 100% of WLPL's paid-up share capital through cash consideration. The new subsidiary will operate in the pharmaceutical sector, with the object to manufacture, develop, and sell pharmaceutical products, including active pharmaceutical ingredients, finished formulations, and key starting materials. As a newly incorporated entity, WLPL has no prior turnover. No governmental or regulatory approvals were required for its incorporation.

Indoco Remedies Ltd has announced the closure of its trading window for dealing in equity shares. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The trading window will be shut from October 1, 2026, until 48 hours after the declaration of the Unaudited Standalone and Consolidated Financial Results for the Quarter and Half Year Ended September 30, 2026. During this period, all designated persons and their immediate relatives are prohibited from trading in the company's shares. The specific date for the Board Meeting to approve these financial results will be communicated separately.

Indoco Remedies Ltd has been assigned an ESG rating of "Crisil ESG 60" by Crisil ESG Ratings & Analytics Limited. The company clarified that it did not engage Crisil for this rating, and it was independently prepared based on publicly available information. This rating provides an external assessment of the company's environmental, social, and governance practices.

Indoco Remedies Ltd announced that its Committee of Executive Directors has approved the incorporation of a wholly owned subsidiary, 'Warren Lifesciences Private Limited'. The new entity will operate in the pharmaceutical sector, focusing on manufacturing, development, and sales of pharmaceutical products including APIs and finished formulations. The incorporation is subject to regulatory approvals. The subsidiary will have an authorized and paid-up capital of ₹1,00,000, with Indoco Remedies holding 100% shareholding. This move aims to expand the company's business operations in the pharmaceutical domain.

Indoco Remedies Limited announced that its manufacturing facility at Plant I in Goa, which produces solid oral dosage forms, underwent an inspection by the UK Medicines and Healthcare products Regulatory Agency (MHRA) from September 7th to 9th, 2026. The inspection, conducted under current Good Manufacturing Practices (cGMP), concluded without any critical or major observations. This facility is crucial for supplying regulated markets like the UK, Europe, South Africa, New Zealand, Australia, and Canada, contributing approximately 30% to the company's total international business. The successful inspection validates Indoco's robust quality systems and commitment to global standards, reinforcing trust with international partners and enhancing its capacity to serve patients worldwide. The plant also holds approvals from USFDA, TGA-Australia, EU Malta, and WHO-GMP.

Indoco Remedies Ltd has disclosed a transaction under SEBI's substantial acquisition regulations. Ms. Aditi M Panandikar and Persons Acting in Concert (PACs) including Ms. Madhura Suresh Kare, Mr. Suresh G Kare, and Mrs. Aruna Suresh Kare, who are part of the promoter group, acquired a total of 38,930 equity shares from the open market. This acquisition represents a minor increase in their total shareholding, bringing their combined stake to 7.30% of the company's total share capital. The transaction occurred on September 8th and 9th, 2026.

Indoco Remedies Ltd announced that its manufacturing facility at Plant II (Sterile) in Goa underwent an inspection by the United States Food and Drug Administration (USFDA) from August 27 to September 4, 2026. Following the inspection, the company received seven observations in Form 483. Indoco Remedies stated that it is comprehensively addressing these observations and will submit its response to the USFDA within the stipulated timeframe. This development is crucial as USFDA compliance is vital for exporting pharmaceutical products to the United States market.

Indoco Remedies Limited has disclosed that Ms. Aditi M. Panandikar and Ms. Madhura Suresh Kare, who belong to the promoter group, have acquired a total of 4,000 equity shares through open market transactions. This acquisition, totaling 0.004% of the total share capital, slightly increases their combined holding to 5.862%. The transaction occurred on September 1, 2026, and was reported to the stock exchanges on September 2, 2026, in compliance with SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.